Publications
274 results found
OZA AM, GANESAN TS, DORREEN M, et al., 1992, PATTERNS OF SURVIVAL IN PATIENTS WITH ADVANCED HODGKINS-DISEASE (HD) TREATED IN A SINGLE CENTER OVER 20 YEARS, BRITISH JOURNAL OF CANCER, Vol: 65, Pages: 429-437, ISSN: 0007-0920
- Author Web Link
- Open Access Link
- Cite
- Citations: 9
KHOO D, RILEY J, WAXMAN J, 1992, CONTROL OF EMESIS IN BOWEL OBSTRUCTION IN TERMINALLY ILL PATIENTS, LANCET, Vol: 339, Pages: 375-376, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 27
Waxman J, Barton C, Biruls R, et al., 1992, Bladder cancer: inter-relationships between chemotherapy and radiotherapy., Br J Urol, Vol: 69, Pages: 151-155, ISSN: 0007-1331
There has been increasing interest in the role of chemotherapy as primary treatments for patients with urothelial cancer and because of the poor prognosis of locally advanced tumours with conventional treatment, trials have been initiated comparing radiotherapy with chemotherapy as primary therapies. In this context it is important to assess the relationship between the responses to chemotherapy and radiotherapy, and this we have examined in 64 patients treated with MVMJ (methotrexate, vinblastine, mitozantrone and carboplatin). Either a complete or a partial response was found in 29 of the 64 patients, 15 had stable disease and 13 had progression of disease. Seven patients died within the first treatment month. The survival of the responding patients ranged from 114 to 1184 days. Six of 15 patients who had had pelvic irradiation prior to chemotherapy responded to MVMJ, the maximum duration of response being more than 3 years. Twenty-two patients had radiotherapy following their chemotherapy. One of 13 patients not responding to MVMJ had a transient response to radical radiotherapy. Only 1 of 9 patients responding to chemotherapy and then relapsing responded to subsequent radical radiotherapy. Patients with metastatic disease or with recurrent disease after radiotherapy have a worthwhile chance of responding to chemotherapy and achieve durable remissions. In contrast, radiotherapy appears relatively ineffective in patients whose disease progresses or relapses after chemotherapy given as primary treatment with curative intent.
SAINI A, WAXMAN J, 1992, RECENT PROGRESS IN THE TREATMENT OF ADVANCED PROSTATIC-CANCER, BRITISH JOURNAL OF HOSPITAL MEDICINE, Vol: 47, Pages: 122-&, ISSN: 0007-1064
Saini A, Waxman J, 1992, Recent progress in the treatment of advanced prostatic cancer., Br J Hosp Med, Vol: 47, Pages: 122-126, ISSN: 0007-1064
Prostatic cancer is the second most common cause of male cancer-related deaths in the UK. Its incidence has almost doubled over the last 30 years, and this may relate to lifestyle, diet, and environmental factors, and far exceeds the changes expected from demographic trends and increased diagnosis.
THOMAS H, BARTON C, SAINI A, et al., 1992, SEQUENTIAL INTERLEUKIN-2 AND ALPHA-INTERFERON FOR RENAL-CELL CARCINOMA AND MELANOMA, EUROPEAN JOURNAL OF CANCER, Vol: 28A, Pages: 1047-1049, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 7
WAXMAN J, GUTIERREZ A, 1992, A EUROPEAN INITIATIVE FOR PROSTATIC-CANCER, EUROPEAN JOURNAL OF CANCER, Vol: 28A, Pages: 1937-1938, ISSN: 0959-8049
WAXMAN J, SAINI A, 1991, THE CURRENT STATUS OF SCIENTIFIC-RESEARCH AND HORMONAL TREATMENTS FOR CARCINOMA OF THE PROSTATE, BRITISH JOURNAL OF CANCER, Vol: 64, Pages: 419-421, ISSN: 0007-0920
- Author Web Link
- Open Access Link
- Cite
- Citations: 7
SAINI A, WAXMAN J, 1991, MANAGEMENT OF CARCINOID-SYNDROME, POSTGRADUATE MEDICAL JOURNAL, Vol: 67, Pages: 506-508, ISSN: 0032-5473
- Author Web Link
- Cite
- Citations: 4
WYNICK D, REES AJ, WAXMAN J, et al., 1991, MEDICAL REGISTRAR TRAINING, BRITISH MEDICAL JOURNAL, Vol: 302, Pages: 595-595, ISSN: 0959-8138
- Author Web Link
- Cite
- Citations: 1
WILSON CB, SNOOK DE, DHOKIA B, et al., 1991, QUANTITATIVE MEASUREMENT OF MONOCLONAL-ANTIBODY DISTRIBUTION AND BLOOD-FLOW USING POSITRON EMISSION TOMOGRAPHY AND I-124 IN PATIENTS WITH BREAST-CANCER, INTERNATIONAL JOURNAL OF CANCER, Vol: 47, Pages: 344-347, ISSN: 0020-7136
- Author Web Link
- Cite
- Citations: 73
WAXMAN J, 1991, A NEW UNDERSTANDING OF THE HORMONAL-REGULATION OF ENDOCRINE DEPENDENT CANCER, BRITISH MEDICAL BULLETIN, Vol: 47, Pages: 197-208, ISSN: 0007-1420
- Author Web Link
- Cite
- Citations: 5
Qayum A, Gullick WJ, Waxman J, 1991, Gonadotrophin-releasing hormone: physiological significance and relevance to cancer., Prog Growth Factor Res, Vol: 3, Pages: 115-130, ISSN: 0955-2235
Gonadotrophin releasing hormone (GnRH) is a decapeptide released by the hypothalamus. The binding of the peptide to pituitary receptors leads to the activation of second messenger systems. The physiological outcome of the exposure of pituitary cells to GnRH is the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). Continued exposure of these receptors to high concentrations of the peptide desensitises the receptor, thus inhibiting the release of gonadotrophins. This paradoxical effect has proved to be beneficial in the clinic where long-acting and enzyme-resistant analogues are used to inhibit the pituitary-gonadal axis, for example in the treatment of advanced prostatic cancer. In addition GnRH-analogues may affect tumour cells directly as observed in vitro. These direct effects have been described as inhibitory but recent data suggests that low concentrations of GnRH-analogues may stimulate short term growth of prostatic cancer cells in vitro. GnRH shares many other common characteristics with peptide growth factors, including common second messenger systems and receptor desensitisation on prolonged exposure to the ligand. It is possible that the direct inhibitory effects of GnRH-analogues are mediated through the desensitisation of tumour GnRH receptors, as suggested by recent observations. The nature and mechanism of the direct anti-tumour effect is important to understand and to promote the therapeutic efficacy of GnRH-analogues in the clinic.
QAYUM A, GULLICK WJ, MELLON K, et al., 1990, THE PARTIAL-PURIFICATION AND CHARACTERIZATION OF GNRH-LIKE ACTIVITY FROM PROSTATIC BIOPSY SPECIMENS AND PROSTATIC-CANCER CELL-LINES, JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, Vol: 37, Pages: 899-902, ISSN: 0960-0760
- Author Web Link
- Cite
- Citations: 34
QAYUM A, GULLICK W, ABEL P, et al., 1990, DIRECT EFFECTS OF GNRH ANALOGS IN PROSTATIC-CANCER, BRITISH JOURNAL OF CANCER, Vol: 62, Pages: 531-531, ISSN: 0007-0920
BARTON C, WAXMAN J, 1990, EFFECTS OF CHEMOTHERAPY ON FERTILITY, BLOOD REVIEWS, Vol: 4, Pages: 187-195, ISSN: 0268-960X
- Author Web Link
- Cite
- Citations: 22
QAYUM A, GULLICK W, CLAYTON RC, et al., 1990, THE EFFECTS OF GONADOTROPIN-RELEASING-HORMONE ANALOGS IN PROSTATE-CANCER ARE MEDIATED THROUGH SPECIFIC TUMOR RECEPTORS, BRITISH JOURNAL OF CANCER, Vol: 62, Pages: 96-99, ISSN: 0007-0920
- Author Web Link
- Open Access Link
- Cite
- Citations: 144
WAXMAN J, THOMAS H, 1990, METASTATIC RENAL-CELL CANCER - IS THE OUTLOOK REALLY IMPROVING, POSTGRADUATE MEDICAL JOURNAL, Vol: 66, Pages: 435-440, ISSN: 0032-5473
- Author Web Link
- Cite
- Citations: 2
HARRISON M, JAMES N, BROADLEY K, et al., 1990, SOMATOSTATIN ANALOG TREATMENT FOR MALIGNANT HYPERCALCEMIA, BRITISH MEDICAL JOURNAL, Vol: 300, Pages: 1313-1314, ISSN: 0959-8138
- Author Web Link
- Cite
- Citations: 21
WAXMAN J, 1990, HYPERCALCEMIA - NEW MECHANISMS FOR OLD OBSERVATIONS, BRITISH JOURNAL OF CANCER, Vol: 61, Pages: 647-648, ISSN: 0007-0920
- Author Web Link
- Open Access Link
- Cite
- Citations: 4
THOMAS H, VALLIS KA, WILLIAMS G, et al., 1990, ASCITES INDUCED BY INTERLEUKIN-2 IN THE TREATMENT OF RENAL-CANCER, BRITISH JOURNAL OF UROLOGY, Vol: 65, Pages: 303-305, ISSN: 0007-1331
- Author Web Link
- Cite
- Citations: 1
QAYUM A, GULLICK W, WAXMAN J, 1990, TUMOR ASSOCIATED GONADOTROPIN-RELEASING HORMONE RECEPTORS, EUROPEAN JOURNAL OF CANCER, Vol: 26, Pages: 149-149, ISSN: 0959-8049
WAXMAN J, 1990, CHEMOTHERAPY FOR METASTATIC BLADDER-CANCER - IS THERE NEW HOPE, BRITISH JOURNAL OF UROLOGY, Vol: 65, Pages: 1-5, ISSN: 0007-1331
- Author Web Link
- Cite
- Citations: 4
WAXMAN J, SANDOW J, ABEL P, et al., 1990, 3-MONTHLY GNRH AGONIST (BUSERELIN) FOR PROSTATIC-CANCER, BRITISH JOURNAL OF UROLOGY, Vol: 65, Pages: 43-45, ISSN: 0007-1331
- Author Web Link
- Cite
- Citations: 3
Qayum A, Scaletsky R, Waxman J, 1990, Autocrine stimulation by gonadotrophin-releasing hormone-like factors of human hormone-responsive prostate cancer cells in culture., Prog Clin Biol Res, Vol: 357, Pages: 121-128, ISSN: 0361-7742
WAXMAN J, THOMAS H, 1990, IS THE OUTLOOK CHANGING FOR PATIENTS WITH RENAL-CELL CANCER, EUROPEAN JOURNAL OF CANCER, Vol: 26, Pages: 860-862, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 1
VORAVUD N, FOSTER CS, GILBERTSON JA, et al., 1989, ONCOGENE EXPRESSION IN CHOLANGIOCARCINOMA AND IN NORMAL HEPATIC DEVELOPMENT, HUMAN PATHOLOGY, Vol: 20, Pages: 1163-1168, ISSN: 0046-8177
- Author Web Link
- Cite
- Citations: 78
HAWKINS P, BLOOM SR, CASSAR J, et al., 1989, IMAGING AMYLOIDOSIS IN STILLS DISEASE, BRITISH MEDICAL JOURNAL, Vol: 299, Pages: 848-850, ISSN: 0959-8138
- Author Web Link
- Cite
- Citations: 1
KALOFONOS HP, SACKIER JM, HATZISTYLIANOU M, et al., 1989, KINETICS, QUANTITATIVE-ANALYSIS AND RADIOIMMUNOLOCALIZATION USING IN-111 HMFG1 MONOCLONAL-ANTIBODY IN PATIENTS WITH BREAST-CANCER, BRITISH JOURNAL OF CANCER, Vol: 59, Pages: 939-942, ISSN: 0007-0920
- Author Web Link
- Open Access Link
- Cite
- Citations: 24
SOWANI A, ONG G, DISCHE S, et al., 1989, C-MYC ONCOGENE EXPRESSION AND CLINICAL OUTCOME IN CARCINOMA OF THE CERVIX, MOLECULAR AND CELLULAR PROBES, Vol: 3, Pages: 117-123, ISSN: 0890-8508
- Author Web Link
- Cite
- Citations: 23
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.